ARQT Stock Forecast: Arcutis Biotherapeutics, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering Arcutis Biotherapeutics, Inc. hold a median 12-month price target of $40 — +51.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 69 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Arcutis Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (96): The business earns solid, repeatable profits on what it owns.
Issuance (21): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ARQT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ARQT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +51.7% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Nov 2026 | TD Cowen | Maintains | Buy | $35 → $40 |
| 19 Oct 2026 | Guggenheim | Maintains | Buy | $38 → $44 |
| 15 Oct 2026 | Cantor Fitzgerald | Initiates | Overweight | $48 |
| 6 Aug 2026 | Guggenheim | Maintains | Buy | $35 → $38 |
| 6 Aug 2026 | Morgan Stanley | Maintains | Overweight | $34 → $38 |
| 6 Aug 2026 | Needham | Maintains | Buy | $36 → $40 |
| 7 May 2026 | Needham | Reiterates | Buy | $36 |
| 2 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 27 Feb 2026 | Guggenheim | Maintains | Buy | — |
| 26 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Feb 2026 | Needham | Maintains | Buy | — |
| 26 Feb 2026 | TD Cowen | Maintains | Buy | — |
| 26 Jan 2026 | Needham | Maintains | Buy | — |
| 28 Nov 2025 | Mizuho | Maintains | Outperform | — |
| 30 Oct 2025 | Goldman Sachs | Maintains | Neutral | — |
| 28 Oct 2025 | Needham | Maintains | Buy | — |
| 7 Aug 2025 | Needham | Maintains | Buy | — |
| 25 July 2025 | Goldman Sachs | Initiates | Neutral | — |
| 23 May 2025 | Needham | Reiterates | Buy | — |
| 9 Apr 2025 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ARQT.
This page is one stock. Monday covers all of them.
ARQT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ARQT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Arcutis Biotherapeutics, Inc. returned −3.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ARQT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 124.5×
- Price / sales
- 6.8×
- Price / book
- 14.2×
- EV / EBITDA
- 89.7×
Cheaper than 6% of US stocks
Cheaper than 16% of US stocks
Cheaper than 5% of US stocks
Cheaper than 4% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- 18.8%
- Gross margin
- 91.6%
- Operating margin
- 6.9%
- Net margin
- 5.9%
Higher than 58% of US stocks
Higher than 97% of US stocks
Higher than 58% of US stocks
Higher than 59% of US stocks
- Return on equity
- 14.9%
- Return on assets
- 4.9%
- Dividend yield
- —
Higher than 73% of US stocks
Higher than 75% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Arcutis Biotherapeutics, Inc. has a market value of $3.5B and an enterprise value of $3.4B.
Revenue in the twelve months to 30 June 2026: $464.0M. The latest quarter grew 59.3% year on year.
Net income over the same four quarters: $28.5M, a 6.1% net margin.
Diluted earnings per share, trailing twelve months: $0.21.
Free cash flow in the twelve months to 30 June 2026: $39.2M.
Trailing P/E: 124.5×; forward P/E: 25.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Arcutis Biotherapeutics, Inc. employs 354 people — $1.3M of revenue per employee.
Data provided by Twelve Data
ARQT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ARQT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Arcutis Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ARQT
What is the ARQT stock price forecast for 2026-2027?
The 8 Wall Street analysts covering Arcutis Biotherapeutics, Inc. have a median 12-month price target of $40, with estimates ranging from $34 to $48. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ARQT stock a buy right now?
Of the 8 analysts covering Arcutis Biotherapeutics, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arcutis Biotherapeutics, Inc. 69 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ARQT?
As at 21 Nov 2026, Arcutis Biotherapeutics, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).
Will ARQT stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +51.7% from the last close, and Ticker Nerd's factor model ranks Arcutis Biotherapeutics, Inc. 69 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ARQT stock forecast for 2030?
No analyst covering Arcutis Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARQT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $48 over the next 12 months.
How has ARQT stock performed over the past year?
Arcutis Biotherapeutics, Inc. returned -3.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Arcutis Biotherapeutics, Inc. do?
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing and commercializing therapies for immune-mediated skin diseases. The company’s portfolio centers on ZORYVE, a branded treatment platform that includes topical formulations used in conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and psoriasis in sensitive areas.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing and commercializing therapies for immune-mediated skin diseases. The company’s portfolio centers on ZORYVE, a branded treatment platform that includes topical formulations used in conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and psoriasis in sensitive areas. Arcutis also advances a pipeline of dermatology candidates, including additional topical and systemic programs designed to address inflammatory skin disorders with high unmet medical need. Its research and development approach combines dermatology expertise with targeted drug development against biologically validated pathways, positioning the company as a specialist player in the medical dermatology market. Based in Westlake Village, California, Arcutis Biotherapeutics serves patients, dermatology clinicians, and healthcare providers through prescription therapies aimed at chronic skin conditions.
CEO Mr. Todd Franklin Watanabe M.A. · 354 employees · United States · https://www.arcutis.com